Chemed stock jumped 4.2% to about US$539 by the close, which indicates that the market responded positively to the results, but the headline story runs deeper than a single-day move. Q2 adjusted earnings outpaced recent history, with adjusted diluted earnings per share up sharply year on year and VITAS hospice margins comfortably above internal expectations.

For you as a shareholder, the key point is how those hospice economics influence the longer-term view. Forecast earnings growth, solid cash generation and a P/E sitting below many healthcare peers now sit alongside this stronger quarter. Together, these factors frame the valuation debate that follows.

Is Chemed trading at a genuine discount to its estimated US$680.94 future cash flow value, or are the softer margins and insider selling already priced in? Compare the current P/E, cash flow assumptions and margin trends against our valuation analysis for Chemed

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$673.251m vs. US$618.798m (up 8.8%)
• Net Income, Q2 2026 vs. Q2 2025: US$67.703m vs. US$52.493m (up 29.0%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$5.14 vs. US$3.60 (up 42.9%)
• VITAS Adjusted EBITDA Margin, Q2 2026 vs. Q2 2025: 18.2% compared with the prior year period (improved, with margin comfortably above internal expectations)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Chemed's full financial picture, including a simple valuation breakdown, in the company report for Chemed.

Chemed bull case: hospice and cash flow milestones

Bulls argue that Chemed is a high quality, cash generative compounder, with VITAS returning to a healthier growth and margin profile while Roto Rooter quietly funds the story. Q2 gives that view more substance. VITAS revenue grew 11.9% to US$443.3m, with days of care up 6.1% and admissions up 9%. Average daily census moved above 24,000 by quarter end, which supports the thesis that the admission mix shift toward longer stays is taking hold. Adjusted EBITDA margin of 18.2% and a small US$0.5m Medicare Cap accrual, with none in Florida and added cap “cushion,” hit key hospice risk milestones. At the group level, adjusted EPS rose more than 40% and operating cash flow was about US$173m. That leaves Chemed with low leverage and capacity for M&A, de novos and franchise buybacks, all core to the long term growth narrative.

Chemed bear case: execution, Roto Rooter and regulatory risks

The bear story centers on fragile execution at VITAS, heavier digital marketing dependency at Roto Rooter and recurring Medicare or billing risks. Q2 softens some of those concerns but does not remove them. Florida Medicare Cap exposure, which worried investors through 2025, is largely cleared, and Q2 added roughly US$8.9m to the cushion. That pushes regulatory risk further out but does not neutralize it. At Roto Rooter, total leads fell 1.6% while paid leads rose to 59% of volume and marketing spend increased by about US$3.1m. Adjusted EBITDA of US$48.5m was flat with margin down 77 bps, so the higher paid lead mix is still pressuring profitability. Water restoration revenue declined 6.7% with revenue per job lower, which keeps the billing and insurer dispute narrative alive even though branch commercial revenue of US$56.8m grew and partly offset contractor weakness.

Reveal where the surface looks calm, but the multi year models start to disagree on Chemed's path from Q2 hospice margins, cash flow and Roto Rooter profitability. Access the full revenue, EPS and free cash flow analyst estimates for Chemed.

Stay Ahead With Chemed Insights

If Chemed's Q2 shift in hospice margins and cash flow has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and wait for a setup that suits you. After you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the updates that actually affect your thesis. For a longer term view, tap into the collective thinking of other investors through the Community. Spot potential catalysts and emerging risks early so you can respond before the wider market catches on.

Seeking Alternatives Beyond Chemed?

Fresh stock ideas can move from quiet buildup to breakout momentum quickly. Use these curated shortlists before the crowd catches what is flying or dropping under the radar for now. Act now.

• Spot sturdy growers that pair cash strength with resilient balance sheets by scanning the list of solid balance sheet and fundamentals stocks (48 results).
• Chase early momentum in sectors quietly building before a breakout by running through the curated 21 high quality undiscovered gems.
• Target steady payers that aim to keep income flowing even when prices move around by checking the hand picked 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.